Seungil Ro

Founder, Chief Scientific Officer at RosVivo Therapeutics

Dr. Seungil Ro Ph.D. is an Associate Professor and Principal Investigator at the University of Nevada in Reno, Nevada. He has researched gastrointestinal motility disorders and their molecular mechanisms for over 20 years. Dr. Ro is highly respected and published researcher. Dr. Ro has made some profound discoveries. He has identified key metabolic molecules responsible for the onset and development of Type 2 Diabetes (T2D). His studies have shown the depletion of these key metabolic molecules also leads to the development of obesity, fatty acid liver disease, gastroparesis and hyperlipidemia. His studies have shown the restoration of these endogenous molecules reverses these disease states. His work has resulted in multiple IPs and patents and the formation of RosVivo Therapeutics.


  • Founder, Chief Scientific Officer

    Current role